Determination of anticancer effects of Urospermum picroides against Different Human Cancer Cell Lines

Main Article Content

Hatice Güneş Mehlika Alper

Abstract

Plants continue to be a good source for developing effective anticancer agents. In this study, in vitro various biological effects of crude ethanolic extract from flowering parts of Urospermum picroides collected from the Muğla province of Turkey were investigated for the first time. Daudi, A549 and HeLa cancer cell lines and BEAS-2B normal cell line were used to identify the cytotoxic effect of the extract using MTT assay. The effect of the extract on cell cycle progression was detected by flow cytometric analysis. The level of VEGF, IL-1α, IL-6 and TNF-α secretion in the cells treated with the extract were measured using ELISA The extract caused a higher cytotoxic effect on Daudi cells with an IC50 value of 85.64 µg/mL than the other cells tested. The IC50 values in HeLa and A549 cells were determined to be 135.35 and 234.8 µg/ mL, respectively. The selective cytotoxicity was considered between Daudi and BEAS-2B (109.80 µg/mL) cell lines. In addition, the effect of the extract on cell cycle progression changes according to cell line used. Moreover, the extract decreased the level of secreted VEGF in treated A549 cells by 31%. In addition, the extract resulted in a significant decrease in the secretion of IL-1α, IL-6 and TNF-α cytokines in A549 and Daudi cells compared to the untreated cells. These findings suggest that the flowering parts of U. picroides may be a potential source for anticancer agents.

Article Details

Section
Sending to International Journal of Secondary Metabolite
Author Biography

Hatice Güneş, Muğla Sıtkı Koçman University

Molecular Biology, Biotechnology, Cancer Biology

References

[1]. World Health Organization. World health statistics 2017: monitoring health for the SDGs, Sustainable Development Goals. Geneva: World Health Organization; 2017.

[2]. Unnati, S., Ripal, S., Sanjeev, A., Niyati, A. (2013). Novel anticancer agents from plant sources. Chin J Nat Me., 11, 16-23.

[3]. Cragg, G.M., Newman, D.J. (2013). Natural products: A continuing source of novel drug leads. Biochim Biophys Acta, 1830, 3670-3695.

[4]. Kintzios, S.E. (2006). Terrestrial Plant-Derived Anticancer Agents and Plant Species Used in Anticancer Research. CRC Crit Rev Plant Sci, 25, 79-113.

[5]. Güner, A., Aslan, S., Ekim, T., Vural, M., Babaç, M. T. (2012). Türkiye Bitkiler Listesi (Damarlı Bitkiler). Nezahat Gökyiğit Botanik Bahçesi Yayını, İstanbul, 1290s.

[6]. Łuczaj, L., Zovko Končić, M., Miličević, T., Dolina, K., Pandža, M. (2013). Wild vegetable mixes sold in the markets of Dalmatia (southern Croatia). J Ethnobiol Ethnomed, 9, 1-12.

[7]. Strzelecka, M., Bzowska, M., Kozieł, J., Szuba, B., Dubiel, O., Riviera Núńez, D., Heinrich, M., Bereta, J. (2005). Anti-inflammatory effects of extracts from some traditional Mediterranean diet plants. J Physiol Pharmacol, 56, 139-156.

[8]. Fragopoulou, E., Detopoulou, P., Nomikos, T., Pliakis, E., Panagiotakos, D.B., Antonopoulou, S. (2012). Mediterranean wild plants reduce postprandial platelet aggregation in patients with metabolic syndrome. Metabolism, 61, 325-334.

[9]. El-Nabawy, H.I., Ayyad, D.M., Serag, M.S., Abdel-Mogib, M. (2015). Phytochemical and Biological Evaluation of Urospermum Picroides. Mansoura J Chem, 19-31.

[10]. El-Amier, Y.A., Al-hadithy, O.N., Abdullah, T.J. (2016). Antioxidant and Antimicrobial Activity of Different Extracts Obtained from Aerial Parts of Urospermum picroides (L.) F.W. from Egypt. J Adv Chem Sci, 2, 299-301.

[11]. Giner, R.M., Cuéllar, M.J., Recio, M.C., Máñez, S., Ríos, J.L. (1992). Chemical Constituents of Urospermum picroides. Z Naturforsch, 47c, 531-534.

[12]. Balboul, B.A.A.A., Ahmed, A.A., Otsuka, H. (1997). Sesquiterpene Lactones and Glucosides from Urospermum picroides. Phytochemistry, 45, 369-373.

[13]. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.

[14]. Denizot, F., Lang, R. (1986) Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods, 89, 271-277.

[15]. Koyama, S., Sato E, Tsukadaira A, Haniuda M, Numanami H, Kurai M, Nagai S, Izumi T. (2002). Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J, 20, 1449-1456

[16]. Nör, J.E., Christensen J, Mooney DJ, Polverini PJ. (1999) Vascular endothelial growth factor (vegf)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of bcl-2 expression. Am J Pathol, 154, 375-384.

[17]. Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., Sarkar, S. (2014). Drug Resistance in Cancer: An Overview. Cancers, 6, 1769-1792.

[18]. Cragg, G.M., John M. Pezzuto, J. M. (2016). Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. Med Princ Pract, 25, 41-59.

[19]. Metwally, A.M., Saleh, M.R.I., Amer, M.M.A. (1973). Isolation of two flavonoidal principles from Urospermum picroides. Planta Med, 23, 94-98.

[20]. Amer, M.M.A., Salama, O. M., Bohlmann, F., Ziesche, J. (1984). Urospermal, a glucoside from Urospermum picroides. Phytochemistry, 23, 692-693.

[21]. Hanahan, D., Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.

[22]. Shapiro, G.I., Harper, J.W. (1999). Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest, 104, 1645-1653.

[23]. Nishida, N., Yano H, Nishida T, Kamura T, Kojiro M. (2006). Angiogenesis in Cancer. Vasc Health Risk Manag, 2, 213-219.

[24]. Carmeliet P. (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology, 69, 4-10.

[25]. Coussens, L.M., Werb, Z. (2002) Inflammation and cancer. Nature, 420, 860-867.

[26]. Kuninaka, S., Yano, T., Yokoyama, H., Fukuyama, Y., Terazaki, Y., Uehara, T., Kanematsu, T., Asoh, H., Ichinose, Y. (2000). Direct influences of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) on the proliferation and cell-surface antigen expression of cancer cells. Cytokine, 12, 8-11.